Literature DB >> 16331263

Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases.

S C Sridhar1, C K Miranti.   

Abstract

KAI1/CD82, a tetraspanin protein, was first identified as a metastasis suppressor in prostate cancer. How loss of CD82 expression promotes cancer metastasis is unknown. Restoration of CD82 expression to physiological levels in the metastatic prostate cell line PC3 inhibits integrin-mediated cell migration and invasion, but does not affect integrin expression. Integrin-dependent activation of the receptor kinase c-Met is dramatically reduced in CD82-expressing cells, as is c-Met activation by its ligand HGF/SF. CD82 expression also reduced integrin-induced activation and phosphorylation of the cytoplasmic tyrosine kinase Src, and its downstream substrates p130Cas and FAK Y861. Inhibition of c-Met expression or Src kinase function reduced matrigel invasion of PC3 cells to the same extent as CD82 expression. These data indicate that CD82 functions to suppress integrin-induced invasion by regulating signaling to c-Met and Src kinases, and suggests that CD82 loss may promote metastasis by removing a negative regulator of c-Met and Src signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16331263     DOI: 10.1038/sj.onc.1209269

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  57 in total

Review 1.  Tetraspanins and tumor progression.

Authors:  Mekel M Richardson; Lisa K Jennings; Xin A Zhang
Journal:  Clin Exp Metastasis       Date:  2010-12-24       Impact factor: 5.150

Review 2.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

Review 3.  Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application.

Authors:  Carrie W Rinker-Schaeffer; James P O'Keefe; Danny R Welch; Dan Theodorescu
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

Review 4.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

5.  Expression of the metastasis suppressor KAI1 in decidual cells at the human maternal-fetal interface: Regulation and functional implications.

Authors:  Birgit Gellersen; Juliane Briese; Marine Oberndörfer; Katja Redlin; Annemarie Samalecos; Dagmar-Ulrike Richter; Thomas Löning; Heinrich-Maria Schulte; Ana-Maria Bamberger
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

6.  Reorganization of the integrin alpha2 subunit controls cell adhesion and cancer cell invasion in prostate cancer.

Authors:  Severine Van Slambrouck; Aaron R Jenkins; Anntherese E Romero; Wim F A Steelant
Journal:  Int J Oncol       Date:  2009-06       Impact factor: 5.650

Review 7.  Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains.

Authors:  Adriane Regina Todeschini; Sen-itiroh Hakomori
Journal:  Biochim Biophys Acta       Date:  2007-10-22

8.  Integrin α3β1 regulates tumor cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization.

Authors:  Afshin Varzavand; Justin M Drake; Robert U Svensson; Mary E Herndon; Bo Zhou; Michael D Henry; Christopher S Stipp
Journal:  Clin Exp Metastasis       Date:  2012-12-06       Impact factor: 5.150

9.  A role for KAI1 in promotion of cell proliferation and mammary gland hyperplasia by the gp78 ubiquitin ligase.

Authors:  Bharat Joshi; Lei Li; Ivan R Nabi
Journal:  J Biol Chem       Date:  2010-01-20       Impact factor: 5.157

10.  ALY as a potential contributor to metastasis in human oral squamous cell carcinoma.

Authors:  Yasuhiro Saito; Atsushi Kasamatsu; Ayumi Yamamoto; Toshihiro Shimizu; Hidetaka Yokoe; Yosuke Sakamoto; Katsunori Ogawara; Masashi Shiiba; Hideki Tanzawa; Katsuhiro Uzawa
Journal:  J Cancer Res Clin Oncol       Date:  2012-12-15       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.